| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/29/2008 | WO2008061370A1 Diagnostic method to detect endometriosis |
| 05/29/2008 | WO2008041003A3 Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorers asociated therewith |
| 05/29/2008 | WO2008038302A3 Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. |
| 05/29/2008 | WO2008021532A3 Treatment of inflammatory diseases |
| 05/29/2008 | WO2007149283A3 Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| 05/29/2008 | WO2007130842A3 Combination therapy for diseases involving angiogenesis |
| 05/29/2008 | WO2007130353A3 Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress |
| 05/29/2008 | WO2007106503A3 Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| 05/29/2008 | WO2006137597A9 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
| 05/29/2008 | US20080125472 Use of an inhibitor of the renin-angiotensin system; candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan, and eprosartan |
| 05/29/2008 | US20080125457 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 05/29/2008 | US20080125447 Combination Therapy |
| 05/29/2008 | US20080125443 nonanalgesic, nonpeptide; for combating ischemic damage and/or effectuating ischemic preconditioning; preservative solution for organ transplants; 4-{(2R,5S)-4-[(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl]-2,5-d- imethyl-1-piperazinylmethyl} benzoic acid |
| 05/29/2008 | US20080125422 Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| 05/29/2008 | US20080125353 Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus |
| 05/29/2008 | US20080124772 Using cytochrome P450 related enzymes comprising high regio- and enantioselectivity for the production of flavor, fragrance, pharmaceutical or bio-control agents |
| 05/29/2008 | US20080124743 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (u1) |
| 05/29/2008 | US20080124401 Method of treating endothelial injury |
| 05/29/2008 | US20080124375 Device and Methods of Sequential, Regional Delivery of Multiple Cyctotoxic Agents and Directed Assembly of Wound Repair Tissues |
| 05/29/2008 | US20080124366 Methods and Compositions for Treating Tumors |
| 05/29/2008 | US20080124348 Immune regulation |
| 05/29/2008 | US20080124336 Molecules and Methods for Inhibiting Shedding of KIM-1 |
| 05/29/2008 | US20080124329 Conditioned Cell Immunization |
| 05/29/2008 | US20080124323 Using fructooligosaccharides as components of probiotics for use in prevention and treatment of infection |
| 05/29/2008 | US20080124322 Activation and inhibition of the immune system |
| 05/29/2008 | US20080124313 Nucleotide sequences coding methionyl tRNA synthetase protein for use in identifying modulators for prevention and treatment of bacterial infection |
| 05/29/2008 | US20080124307 Method for promoting immunotherapy |
| 05/29/2008 | US20080124306 Vigor Enhancement Via Administration of Pyrimidine Derivatives |
| 05/29/2008 | US20080124301 Oligonucleotide for use in prevention and treatment of cell proliferative and nervous system disorders; antisense agents |
| 05/29/2008 | CA2683114A1 Cells expressing alpha-synuclein and uses therefor |
| 05/29/2008 | CA2670439A1 Anticonvulsive pharmaceutical compositions |
| 05/29/2008 | CA2670405A1 Combination treatments for alzheimer's disease and related neurodegenerative diseases |
| 05/29/2008 | CA2670288A1 Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| 05/29/2008 | CA2670160A1 Methods for improving bioavailability of a renin inhibitor |
| 05/29/2008 | CA2669982A1 Combination therapy for proliferative disorders |
| 05/29/2008 | CA2668652A1 Inhibitors of voltage-gated ion channels for use in treating pain and pruritis |
| 05/29/2008 | CA2667802A1 Multiple sclerosis therapy |
| 05/28/2008 | EP1925941A1 Method for prediction of the efficacy of vascularization inhibitor |
| 05/28/2008 | EP1925677A2 Marker genes for determining renal toxicity |
| 05/28/2008 | EP1925315A2 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| 05/28/2008 | EP1925309A1 Novel anticancer concomitant drug |
| 05/28/2008 | EP1925306A2 Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure |
| 05/28/2008 | EP1925303A2 Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure |
| 05/28/2008 | EP1924326A1 Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow |
| 05/28/2008 | EP1924289A2 Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents |
| 05/28/2008 | EP1924274A1 Modulation of cell fates and activities by phthalazinediones |
| 05/28/2008 | EP1924250A2 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| 05/28/2008 | EP1924146A2 A method for cell implantation |
| 05/28/2008 | EP1741425B1 Novel antiviral pharmaceutical composition |
| 05/28/2008 | EP1701741B1 Complexes having adjuvant activity |
| 05/28/2008 | EP1691805B1 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person |
| 05/28/2008 | EP1660475B1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 05/28/2008 | EP1620069B1 Warming and nonirritating lubricant fungicide compositions in the form of a gel |
| 05/28/2008 | EP1592449B1 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 05/28/2008 | EP1537243B1 Method of diagnosing ovarian endometriosis |
| 05/28/2008 | EP1496898B1 Tyrosine kinase inhibitors |
| 05/28/2008 | EP1485354B1 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 05/28/2008 | EP1473305B1 Novel glutamate receptor and utilization thereof |
| 05/28/2008 | EP1471895B1 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| 05/28/2008 | EP1425031B1 Hdl for the treatment of stroke and other ischemic conditions |
| 05/28/2008 | EP1404864A4 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| 05/28/2008 | EP1399744B1 Epf receptor assays, compounds and therapeutic compositions |
| 05/28/2008 | EP1391194B1 Preparation for hair and/or scalp |
| 05/28/2008 | EP1370684B1 Polynucleotides related to colon cancer |
| 05/28/2008 | EP1343806B1 Methylene steroids as novel androgens |
| 05/28/2008 | EP1326630B1 Use of glp-2 peptides |
| 05/28/2008 | EP1301604B1 Substrates and assays for beta-secretase activity |
| 05/28/2008 | EP1218360B1 Triazine kinase inhibitors |
| 05/28/2008 | EP1165095B1 Agents for intravitreal administration to treat or prevent disorders of the eye |
| 05/28/2008 | EP1005485B1 Therapeutic pulmonary lavage with diluted surfactants |
| 05/28/2008 | CN101189219A Preventive or remedy for depression or anxiety neurosis |
| 05/28/2008 | CN101189044A Pharmaceutical composition containing an anti-fungus agent and one active substance selected from carveol, eugenol, thymol, borneol, carvacrol, alpha-ionone and beta-ionone |
| 05/28/2008 | CN101189005A Combinations of a squalene synthase inhibitor and a HMG-CoA reductase inhibitor for treating hyperlipidemia |
| 05/28/2008 | CN101186928A Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
| 05/28/2008 | CN101185759A Anti-angiogene compositions and methods of use |
| 05/28/2008 | CN101185758A Composite medicine for treating toothache quickly and effectively |
| 05/28/2008 | CN101185652A Remedies for lung cancer |
| 05/28/2008 | CN101185624A Novel composing prescription sustained-release preparation for treating high blood pressure and preparation method thereof |
| 05/28/2008 | CN100390288C Multivalent antibodies and uses therefor |
| 05/28/2008 | CN100390195C Modulators of function of FAS receptors and other proteins |
| 05/28/2008 | CN100390170C 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active |
| 05/28/2008 | CN100390135C Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 05/28/2008 | CN100389830C Medicinal composition for treating high blood pressure |
| 05/28/2008 | CN100389829C Identification method of compound for inhibiting tumour injury and medicinal compositions containing said compound |
| 05/28/2008 | CN100389828C Medicines comprising Rho kinase inhibitor |
| 05/28/2008 | CN100389821C Stabilized liquid polypeptide-containing pharmaceutical composition |
| 05/28/2008 | CN100389773C Novel helicobacter pylori-binding substances and use thereof |
| 05/28/2008 | CN100389771C Use of composition comprising Formoterol and Budesonide for prevention or treatment of acute condition of asthma |
| 05/27/2008 | US7378519 enantiomerically pure 1S,2S-tramadol hydrochloride by dissolving topiramate and tramadol hydrochloride; cooling; crystallization; filtration; separating the 1S,2S-tramadol hydrochloride from the mother liquor by chromatography or crystallization |
| 05/27/2008 | US7378445 Treatment of prostate cancer |
| 05/27/2008 | US7378438 Asthma; side effect reduction; converting SH groups to SNO groups of N-benzylphthalimide usingHCl and NaNO2; epoxide or thioepoxid of N-benzylphthalimide; amination; 5-{2-[(1-Yloxyl-2,2,5,5-tetramethyl-pyrrolidin-3-ylmethyl)-amino]-1-S-nitroso-ethyl}-1,1,3,3-tetramethylisoindolin-2-yloxyl, hydrochloride |
| 05/27/2008 | US7378422 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 05/27/2008 | US7378411 Substituted thienopyrimidinones as a mitotic kinesin inhibitor |
| 05/27/2008 | US7378406 11 beta -(4-acetylphenyl)-17 beta-hydroxy-17-alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a derivative, especially for prophylaxis and treatmenet of breast cancer |
| 05/27/2008 | US7378389 Neurotoxic component has been purified from a botulinum toxin by fermenting a Clostridium botulinum to botulinum toxin type A; promotion of normal muscle growth |
| 05/27/2008 | US7378274 Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses |
| 05/27/2008 | US7378247 Tumor preferential polypeptide for use in the prevention treatment and diagnosis of cell proliferative disorders |
| 05/27/2008 | US7378097 Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant |
| 05/27/2008 | US7378077 Hydrating a leukemia patient; parenterally administering a dose samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and melphalan, busulfan, and/or cyclophosphamiide; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders |
| 05/27/2008 | CA2455115C Pharmaceutical aerosol formulation |